The results of the DESTINY-Breast04 trial showed significant efficacy of HER2 target therapy with trastuzumab deruxtecan in patients with HER2-low expressing breast cancer, providing another insight into the interpretation of the current study [14]. This evidence concerns the gene ERBB2 and breast carcinoma.